Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion type Assertion NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_head.
- NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion description "[Blockade of VEGFR2 signaling using DC101 anti-VEGFR2 monoclonal antibody enhanced doxorubicin chemoresponse; this combined biochemotherapy inhibited tumor growth and decreased pulmonary metastases without overt toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_provenance.
- NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion evidence source_evidence_literature NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_provenance.
- NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion SIO_000772 16951193 NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_provenance.
- NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion wasDerivedFrom befree-2016 NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_provenance.
- NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_assertion wasGeneratedBy ECO_0000203 NP567509.RAH0rtvPqVaq-mss1og_2x1unJlI_YdyfYookxLmpxkak130_provenance.